<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083990</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI305A201</org_study_id>
    <nct_id>NCT03083990</nct_id>
  </id_info>
  <brief_title>Compare IBI305 and Bevacizumab on Pharmacokinetics/Safety/Immunogenicity on Healthy Male</brief_title>
  <official_title>Compare IBI305 to Avastin on the Pharmacokinetics, Safety, Tolerance and Immunogenicity of a Single Dose In Healthy Male Subjects: a Randomized Double-blind Parallel Controlled Phase I Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To confirm the PK similarity of IBI305 and bevacizumab in healthy volunteers .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Actual">August 17, 2017</completion_date>
  <primary_completion_date type="Actual">August 17, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC0 - t</measure>
    <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
    <description>the area under the blood drug concentration time curve form 0 to t (AUC0 - t)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0 - ∞</measure>
    <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
    <description>the area under the blood drug concentration time curve form 0 to ∞AUC0 - ∞)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2</measure>
    <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
    <description>elimination half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance Rate</measure>
    <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
    <description>apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution</measure>
    <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
    <description>apparent volume of distribution(V）</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants Positive for Nab（Neutralizing Antibody）</measure>
    <time_frame>99 days after administration</time_frame>
    <description>The analysis of NAb was done by Covance Pharmaceutical R&amp;D (Shanghai) Co., Ltd. using methodologically validated ECL immunoassay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants Positive for Anti-drug Antibodies</measure>
    <time_frame>99 days after administration</time_frame>
    <description>The analysis of ADA was done by Wuxi AppTec (Shanghai) Co., Ltd. using methodologically validated electrochemiluminescence (ECL) immunoassay.</description>
  </other_outcome>
  <other_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>0, D1( immediately after the end of infusion), D1 (4 hrs after the start of infusion), D1, 8 hrs after the start of infusion, D1 (12 hrs after the start of infusion), D2, D3, D5, D8, D15, D22, D29, D43, D57, D64, D71, D85, D99</time_frame>
    <description>Systolic blood pressure and diastolic blood pressure on certain timepoints are measured and recorded.</description>
  </other_outcome>
  <other_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>0, D1( immediately after the end of infusion), D1 (4 hrs after the start of infusion), D1, 8 hrs after the start of infusion, D1 (12 hrs after the start of infusion), D2, D3, D5, D8, D15, D22, D29, D43, D57, D64, D71, D85, D99</time_frame>
    <description>Systolic blood pressure and diastolic blood pressure on certain timepoints are measured and recorded.</description>
  </other_outcome>
  <other_outcome>
    <measure>Urinalysis</measure>
    <time_frame>Baseline,D2,D5,D15,D29,D57,D71,D99</time_frame>
    <description>Urine specific gravity as assessed by laboratory tests up to 99 days post-treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Baseline,D2,D5,D15,D29,D57,D71,D99</time_frame>
    <description>Hemoglobin as assessed by laboratory tests up to 99 days post-treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IBI 305 ,3mg/kg, infusion in 90 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IBI305(Bevacizumab Biosimilar)</intervention_name>
    <description>3mg/kg, infusion in 90minutes</description>
    <arm_group_label>Group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avastin(Bevacizumab)</intervention_name>
    <description>3mg/kg, infusion in 90minutes</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  To be eligible for the study, patients should fulfill all the following criteria:&#xD;
&#xD;
               1. Fully understand the study purpose, and understand the pharmacological effects&#xD;
                  and potential adverse reactions of the drug, voluntarily signed written informed&#xD;
                  consent according to the declaration of Helsinki.&#xD;
&#xD;
               2. Age ≥18 and ≤ 50, healthy male subjects&#xD;
&#xD;
               3. Weigh ≥ 50 kg and ≤ 100 kg， BMI≥ 19 and ≤ 28 kg/m2&#xD;
&#xD;
               4. All the system test result within the normal range, or abnormal test results&#xD;
                  without clinical significance judged by the investigator.&#xD;
&#xD;
               5. The subjects must agree to use effective contraceptive measures during the study&#xD;
                  treatment and for 6 months after receiving last does of study drug (e.g.&#xD;
                  abstinence, sterilization surgery, oral contraceptives, contraception by&#xD;
                  progesterone injection or subcutaneous)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients should not enter the study if any of the following exclusion criteria are&#xD;
             fulfilled:&#xD;
&#xD;
               1. Medical history of high blood pressure or abnormal blood pressure at&#xD;
                  screening/baseline(Double confirmed systolic blood pressure (SBP) &gt;140 mmHg&#xD;
                  and/or diastolic blood pressure (DBP) &gt; 90 mmHg within one day)&#xD;
&#xD;
               2. Proteinuria with clinical significance judged by the investigator (routine urine&#xD;
                  examination, urine protein 2 + and above) or a history of proteinuria.&#xD;
&#xD;
               3. Any prior VEGF(vascular endothelial growth factor) and VEGFR(Vascular Endothelial&#xD;
                  Growth Factor Receptor) antibody or protein treatment within one year.&#xD;
&#xD;
               4. Any biological products or a live virus vaccine treatment within 3 months , or&#xD;
                  any monoclonal antibodies within 12 months before the first dose of study drug.&#xD;
&#xD;
               5. History or evidence of inherited bleeding diathesis or coagulopathy or thrombus.&#xD;
&#xD;
               6. History of digestive tract perforation or digestive tract fistula.&#xD;
&#xD;
               7. Serious, non-healing wound, active ulcer, or untreated bone fracture, or major&#xD;
                  surgical procedure within 2 months prior to randomization or anticipation of need&#xD;
                  for major surgery during the course of the study or 2 months after last dose of&#xD;
                  the study drug.&#xD;
&#xD;
               8. Use Rx or OTC drugs or nutritional health products within 5 half-lives or within&#xD;
                  2 weeks before the first dose of study drug (According to the longer time).Herbal&#xD;
                  supplements need to stop at 28 days before the first dose of study drug.&#xD;
&#xD;
               9. Positive hepatitis b surface antigen (HBsAg), hepatitis c virus (HCV) antibody,&#xD;
                  or human immunodeficiency virus (HIV) antibody or syphilis&#xD;
&#xD;
              10. Known hypersensitivity to Bevacizumab or any excipients&#xD;
&#xD;
              11. Known allergic disease or allergic constitution&#xD;
&#xD;
              12. History of blood donation within 3 months before the first dose of study drug&#xD;
&#xD;
              13. Treatment with any other investigational agent or participation in another&#xD;
                  clinical trial within 3 months prior to screening&#xD;
&#xD;
              14. History of alcoholism or drug abuse within 12 months prior to screening; Subjects&#xD;
                  cannot temperance within 72 hours before study drug infusion and during the whole&#xD;
                  study&#xD;
&#xD;
              15. History of mental illness&#xD;
&#xD;
              16. Anticipated of partner pregnancy during the study.&#xD;
&#xD;
              17. Incompliance to the clinical study protocol during the study.&#xD;
&#xD;
              18. Other conditions that the investigator thinks unsuitable in this study&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>yanhua Ding, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jilin University First Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jilin University First Hospital</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 12, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2017</study_first_posted>
  <results_first_submitted>July 6, 2020</results_first_submitted>
  <results_first_submitted_qc>October 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 4, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 3, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03083990/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT03083990/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>IBI305</title>
          <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
        </group>
        <group group_id="P2">
          <title>Bevacizumab</title>
          <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline demographics of the subjects were analyzed based on the Pharmacokinetics analysis set.A total of 98 (98.0%) subjects were included , and 2 (4%) subjects in the IBI305 arm were excluded in the due to positive anti-drug antibody at baseline.</population>
      <group_list>
        <group group_id="B1">
          <title>IBI305</title>
          <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
        </group>
        <group group_id="B2">
          <title>Bevacizumab</title>
          <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="98"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Mean (SD)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.5" spread="8.92"/>
                    <measurement group_id="B2" value="34.0" spread="8.87"/>
                    <measurement group_id="B3" value="35.2" spread="8.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Han</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Others</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="169.7" spread="5.69"/>
                    <measurement group_id="B2" value="169.0" spread="5.12"/>
                    <measurement group_id="B3" value="169.3" spread="5.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.32" spread="7.763"/>
                    <measurement group_id="B2" value="68.42" spread="6.629"/>
                    <measurement group_id="B3" value="67.88" spread="7.191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.414" spread="2.739"/>
                    <measurement group_id="B2" value="23.962" spread="2.040"/>
                    <measurement group_id="B3" value="23.694" spread="2.412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AUC0 - t</title>
        <description>the area under the blood drug concentration time curve form 0 to t (AUC0 - t)</description>
        <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
        <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0 - t</title>
          <description>the area under the blood drug concentration time curve form 0 to t (AUC0 - t)</description>
          <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
          <units>h*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19704.2" spread="18.8"/>
                    <measurement group_id="O2" value="20736.9" spread="19.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Geometric mean ratio and its 90%CI are obtained after anti-logarithmic transformation.If 90% CI for the geometric mean ratio of AUC 0-t and AUC 0-∞ (trial/control) ranges between 0.8-1.25, then it is considered that IBI305 and Bevacizumab are bioequivalent.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9502</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8921</ci_lower_limit>
            <ci_upper_limit>1.0120</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>AUC0 - ∞</title>
        <description>the area under the blood drug concentration time curve form 0 to ∞AUC0 - ∞)</description>
        <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
        <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0 - ∞</title>
          <description>the area under the blood drug concentration time curve form 0 to ∞AUC0 - ∞)</description>
          <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
          <units>h*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20180.2" spread="18.6"/>
                    <measurement group_id="O2" value="21281.4" spread="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Geometric mean ratio and its 90%CI are obtained after anti-logarithmic transformation.If 90% CI for the geometric mean ratio of AUC 0-t and AUC 0-∞ (trial/control) ranges between 0.8-1.25, then it is considered that IBI305 and Bevacizumab are bioequivalent.</non_inferiority_desc>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9483</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8896</ci_lower_limit>
            <ci_upper_limit>1.0108</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax</title>
        <description>Maximum serum concentration</description>
        <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
        <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax</title>
          <description>Maximum serum concentration</description>
          <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
          <units>ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="21.0"/>
                    <measurement group_id="O2" value="67.0" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <p_value>&gt;0.05</p_value>
            <method>ANOVA</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9749</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.9123</ci_lower_limit>
            <ci_upper_limit>1.0418</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>t1/2</title>
        <description>elimination half life</description>
        <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
        <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>t1/2</title>
          <description>elimination half life</description>
          <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340.2" spread="51.1"/>
                    <measurement group_id="O2" value="356.5" spread="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance Rate</title>
        <description>apparent clearance</description>
        <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
        <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance Rate</title>
          <description>apparent clearance</description>
          <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
          <units>ml/h/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.151" spread="0.0296"/>
                    <measurement group_id="O2" value="0.144" spread="0.0281"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apparent Volume of Distribution</title>
        <description>apparent volume of distribution(V）</description>
        <time_frame>60 min before intravenous infusion, 5 min after iv. infusion, 4 hr, 12 hr, 2 days, 3 days, 5 days, 8 days, 15 days, 22 days, 29 days, 43 days, 57 days, 64 days, 71 days, 85 days</time_frame>
        <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Apparent Volume of Distribution</title>
          <description>apparent volume of distribution(V）</description>
          <population>2 subjects in the IBI305 arm were not included in the PKAS(PK analysis set) because of positive ADA at baseline</population>
          <units>ml/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.8" spread="15.9"/>
                    <measurement group_id="O2" value="72.3" spread="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Positive for Nab（Neutralizing Antibody）</title>
        <description>The analysis of NAb was done by Covance Pharmaceutical R&amp;D (Shanghai) Co., Ltd. using methodologically validated ECL immunoassay.</description>
        <time_frame>99 days after administration</time_frame>
        <population>All 100 (100%) subjects were included in the NAb-AS (Neutralizing anti-body analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Positive for Nab（Neutralizing Antibody）</title>
          <description>The analysis of NAb was done by Covance Pharmaceutical R&amp;D (Shanghai) Co., Ltd. using methodologically validated ECL immunoassay.</description>
          <population>All 100 (100%) subjects were included in the NAb-AS (Neutralizing anti-body analysis set)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants Positive for Anti-drug Antibodies</title>
        <description>The analysis of ADA was done by Wuxi AppTec (Shanghai) Co., Ltd. using methodologically validated electrochemiluminescence (ECL) immunoassay.</description>
        <time_frame>99 days after administration</time_frame>
        <population>All 100 (100%) subjects were included in the ADA-AS(Anti-drug Antibody Analysis set)</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Positive for Anti-drug Antibodies</title>
          <description>The analysis of ADA was done by Wuxi AppTec (Shanghai) Co., Ltd. using methodologically validated electrochemiluminescence (ECL) immunoassay.</description>
          <population>All 100 (100%) subjects were included in the ADA-AS(Anti-drug Antibody Analysis set)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D43</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Systolic Blood Pressure</title>
        <description>Systolic blood pressure and diastolic blood pressure on certain timepoints are measured and recorded.</description>
        <time_frame>0, D1( immediately after the end of infusion), D1 (4 hrs after the start of infusion), D1, 8 hrs after the start of infusion, D1 (12 hrs after the start of infusion), D2, D3, D5, D8, D15, D22, D29, D43, D57, D64, D71, D85, D99</time_frame>
        <population>All 100 (100%) subjects were included in the safety analysis set. Blood pressure of certain timepoint was not collected because of serve adverse event.</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <description>Systolic blood pressure and diastolic blood pressure on certain timepoints are measured and recorded.</description>
          <population>All 100 (100%) subjects were included in the safety analysis set. Blood pressure of certain timepoint was not collected because of serve adverse event.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.6" spread="8.73"/>
                    <measurement group_id="O2" value="121.4" spread="8.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D1, immediately after the end of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.3" spread="10.23"/>
                    <measurement group_id="O2" value="114.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D1, 4 hrs after the start of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.0" spread="9.60"/>
                    <measurement group_id="O2" value="119.6" spread="7.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D1, 8 hrs after the start of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.4" spread="9.48"/>
                    <measurement group_id="O2" value="120.3" spread="8.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D1, 12 hrs after the start of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.8" spread="8.67"/>
                    <measurement group_id="O2" value="123.4" spread="9.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.8" spread="9.72"/>
                    <measurement group_id="O2" value="121.9" spread="8.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.2" spread="8.37"/>
                    <measurement group_id="O2" value="123.2" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120.7" spread="7.97"/>
                    <measurement group_id="O2" value="121.4" spread="8.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.4" spread="7.69"/>
                    <measurement group_id="O2" value="122.6" spread="9.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.6" spread="9.70"/>
                    <measurement group_id="O2" value="118.5" spread="10.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.8" spread="8.73"/>
                    <measurement group_id="O2" value="122.5" spread="8.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" spread="9.20"/>
                    <measurement group_id="O2" value="123.1" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.7" spread="9.12"/>
                    <measurement group_id="O2" value="121.3" spread="9.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.4" spread="10.30"/>
                    <measurement group_id="O2" value="122.1" spread="8.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.4" spread="8.78"/>
                    <measurement group_id="O2" value="120.2" spread="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.3" spread="10.01"/>
                    <measurement group_id="O2" value="119.8" spread="10.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115.8" spread="9.04"/>
                    <measurement group_id="O2" value="120.6" spread="9.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118.2" spread="7.61"/>
                    <measurement group_id="O2" value="118.2" spread="10.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Diastolic Blood Pressure</title>
        <description>Systolic blood pressure and diastolic blood pressure on certain timepoints are measured and recorded.</description>
        <time_frame>0, D1( immediately after the end of infusion), D1 (4 hrs after the start of infusion), D1, 8 hrs after the start of infusion, D1 (12 hrs after the start of infusion), D2, D3, D5, D8, D15, D22, D29, D43, D57, D64, D71, D85, D99</time_frame>
        <population>All 100 (100%) subjects were included in the safety analysis set. Blood pressure of certain timepoint was not collected because of serve adverse event.</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <description>Systolic blood pressure and diastolic blood pressure on certain timepoints are measured and recorded.</description>
          <population>All 100 (100%) subjects were included in the safety analysis set. Blood pressure of certain timepoint was not collected because of serve adverse event.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="8.02"/>
                    <measurement group_id="O2" value="81.4" spread="5.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D1, immediately after the end of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" spread="7.82"/>
                    <measurement group_id="O2" value="73.7" spread="6.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D1, 4 hrs after the start of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="6.68"/>
                    <measurement group_id="O2" value="77.4" spread="7.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D1, 8 hrs after the start of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="5.94"/>
                    <measurement group_id="O2" value="79.3" spread="6.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D1, 12 hrs after the start of infusion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0" spread="6.96"/>
                    <measurement group_id="O2" value="81.3" spread="7.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.8" spread="6.57"/>
                    <measurement group_id="O2" value="81.6" spread="6.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" spread="6.45"/>
                    <measurement group_id="O2" value="82.8" spread="6.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.4" spread="8.30"/>
                    <measurement group_id="O2" value="82.1" spread="4.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="49"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" spread="6.23"/>
                    <measurement group_id="O2" value="81.4" spread="6.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.2" spread="7.67"/>
                    <measurement group_id="O2" value="79.2" spread="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" spread="6.04"/>
                    <measurement group_id="O2" value="82.3" spread="7.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.6" spread="6.43"/>
                    <measurement group_id="O2" value="81.6" spread="7.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" spread="7.34"/>
                    <measurement group_id="O2" value="80.0" spread="6.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="50"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6" spread="7.87"/>
                    <measurement group_id="O2" value="82.2" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.7" spread="7.33"/>
                    <measurement group_id="O2" value="80.5" spread="6.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" spread="8.01"/>
                    <measurement group_id="O2" value="80.2" spread="6.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.2" spread="6.96"/>
                    <measurement group_id="O2" value="80.0" spread="6.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="49"/>
                    <count group_id="O2" value="50"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.8" spread="6.91"/>
                    <measurement group_id="O2" value="77.9" spread="6.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Urinalysis</title>
        <description>Urine specific gravity as assessed by laboratory tests up to 99 days post-treatment</description>
        <time_frame>Baseline,D2,D5,D15,D29,D57,D71,D99</time_frame>
        <population>All 100 (100%) subjects were included in the analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Urinalysis</title>
          <description>Urine specific gravity as assessed by laboratory tests up to 99 days post-treatment</description>
          <population>All 100 (100%) subjects were included in the analysis set</population>
          <units>Urine specific gravity</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" spread="0.006"/>
                    <measurement group_id="O2" value="1.017" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" spread="0.006"/>
                    <measurement group_id="O2" value="1.017" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" spread="0.005"/>
                    <measurement group_id="O2" value="1.018" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.016" spread="0.006"/>
                    <measurement group_id="O2" value="1.017" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" spread="0.005"/>
                    <measurement group_id="O2" value="1.017" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.016" spread="0.005"/>
                    <measurement group_id="O2" value="1.018" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" spread="0.004"/>
                    <measurement group_id="O2" value="1.016" spread="0.005"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.017" spread="0.006"/>
                    <measurement group_id="O2" value="1.019" spread="0.006"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Hemoglobin</title>
        <description>Hemoglobin as assessed by laboratory tests up to 99 days post-treatment.</description>
        <time_frame>Baseline,D2,D5,D15,D29,D57,D71,D99</time_frame>
        <population>All 100 (100%) subjects were included in the safety analysis set (SS)</population>
        <group_list>
          <group group_id="O1">
            <title>IBI305</title>
            <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
          </group>
          <group group_id="O2">
            <title>Bevacizumab</title>
            <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin</title>
          <description>Hemoglobin as assessed by laboratory tests up to 99 days post-treatment.</description>
          <population>All 100 (100%) subjects were included in the safety analysis set (SS)</population>
          <units>Hemoglobin (g/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.0" spread="9.42"/>
                    <measurement group_id="O2" value="163.5" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158.8" spread="11.53"/>
                    <measurement group_id="O2" value="160.4" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.4" spread="10.93"/>
                    <measurement group_id="O2" value="167.7" spread="10.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.9" spread="10.67"/>
                    <measurement group_id="O2" value="164.5" spread="9.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161.1" spread="10.01"/>
                    <measurement group_id="O2" value="164.5" spread="11.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160.4" spread="12.45"/>
                    <measurement group_id="O2" value="165.5" spread="10.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D71</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.8" spread="12.19"/>
                    <measurement group_id="O2" value="163.9" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>D99</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154.6" spread="11.01"/>
                    <measurement group_id="O2" value="159.9" spread="10.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>from participants are enrolled to 99 days after infusion</time_frame>
      <desc>The analysis population consisted of all participants.</desc>
      <group_list>
        <group group_id="E1">
          <title>IBI305</title>
          <description>IBI 305 ,3mg/kg, infusion in 90 minutes&#xD;
IBI305(Bevacizumab Biosimilar): 3mg/kg, infusion in 90minutes</description>
        </group>
        <group group_id="E2">
          <title>Bevacizumab</title>
          <description>Bevacizumab (Avastin) 3mg/kg, infusion in 90 minutes&#xD;
Avastin(Bevacizumab): 3mg/kg, infusion in 90minutes</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA(19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hand injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA(19.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALT increased</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="50"/>
                <counts group_id="E2" events="17" subjects_affected="12" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>AST increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Bilirubin increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="25" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="24" subjects_affected="13" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="50"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Intermediate insomnia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yi Bo</name_or_title>
      <organization>Innovent Biologics (Suzhou) Co., Ltd. (seal)</organization>
      <phone>+86 13382419112</phone>
      <email>jessica.yi@innoventbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

